Taiwan Liposome Company

Executive Summary

Taiwan Liposome Company (TLC) is a clinical-stage biotechnology firm specializing in lipid-engineered medicines via its proprietary LipAD® platform, which includes BioSeizer®, NanoX®, and Genosphere™ technologies. The company targets orthopedic pain (e.g., osteoarthritis candidates TLC599 and TLC590), metabolic disorders, and in-vivo CAR-T therapies, with a focus on improving drug delivery and efficacy. Notably, TLC has an approved liposomal product in China, demonstrating commercial validation. Its late-stage pipeline is led by TLC599, a long-acting liposomal corticosteroid for osteoarthritis knee pain, currently in Phase 3 trials. TLC590, a liposomal bupivacaine for post-surgical pain, is advancing through registrational studies. The company's in-vivo CAR-T platform, still preclinical, leverages lipid nanoparticles to reprogram immune cells inside the body, potentially simplifying cell therapy. With a strong IP portfolio and a foothold in the Chinese market, TLC is positioned to address unmet needs in pain management and regenerative medicine.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 top-line data for TLC599 in osteoarthritis knee pain70% success
• Q1 2027NDA submission for TLC590 in post-surgical pain60% success
• H2 2027IND filing for lead in-vivo CAR-T candidate40% success